Quantum Biopharma Ltd. (QNTM) intrinsic value & 10-year financials
Quantum Biopharma Ltd. (QNTM) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -81.5%
- Free cash flow (FY2025)
- —
QNTM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | — | — | — | — | — |
| FY2024 | — | — | — | — | — | — |
| FY2023 | — | — | — | — | — | — |
| FY2022 | — | -CAD 23.6M | — | -CAD 28.4M | — | -55.8% |
| FY2021 | — | -CAD 35.3M | — | — | — | -78.0% |
| FY2020 | — | -CAD 31.8M | — | — | — | -87.6% |
| FY2019 | — | -CAD 39.1M | — | — | — | -104.8% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in CAD.
Executive summary
Quantum Biopharma Ltd. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Quantum Biopharma Ltd. 10-year average ROIC is N/A; capital efficiency cannot be assessed from the available history.
Quantum Biopharma Ltd. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Quantum Biopharma Ltd. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.